{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:55:25Z","timestamp":1781862925942,"version":"3.54.5"},"reference-count":29,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Cabozantinib treatment is associated with improved survival in renal cell carcinoma (RCC) patients with bone metastasis. We evaluated the direct effects of cabozantinib on bone metastasis in advanced RCC (aRCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter, open\u2010label study, adult Japanese aRCC patients with bone metastasis received oral cabozantinib 60\u2009mg once daily until drug discontinuation\/data cut\u2010off. The primary endpoint was the objective response rate (ORR) of bone target lesions (modified MD Anderson criteria) evaluated by an independent radiology committee. Secondary endpoints were overall survival (OS), disease control rate (DCR) of bone lesions, progression\u2010free survival (PFS), symptomatic skeletal events (SSEs), bone\u2010specific PFS, and safety. Exploratory endpoints were changes in bone turnover, plasma biomarkers, and health\u2010related quality of life (HRQoL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty\u2010one patients were enrolled (median age, 70.0\u2009years; 64.5% men). The ORR of bone target lesions was 6.5% (90% CI 1.2\u201318.9), DCR was 90.3% (90% CI 76.8\u201397.3), and the median change in bone target lesion size was \u22125.2% (range\u221242.8 to 19.2). Median PFS was 11.9\u2009months (95% CI 5.7\u2013not evaluable), median OS was 24.9\u2009months (95% CI 19.1\u2013not evaluable), and three patients reported SSEs. Bone\u2010specific PFS remained &gt;\u200960% among patients who were evaluable during follow\u2010up. Levels of bone\u2010turnover markers generally decreased; no trends were observed in plasma biomarkers. EQ\u20105D\u20105L index values remained generally stable. Common adverse events were palmar\u2010plantar erythrodysesthesia syndrome (54.8%), malaise (45.2%), diarrhea, abnormal hepatic function (32.3%), and hypertension (32.3%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most aRCC patients showed favorable disease control following cabozantinib treatment. No new safety issues were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>Japan Registry of Clinical Trials (JRCT), registration no. jRCTs031210220<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/iju.70495","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:47:47Z","timestamp":1779695267000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis Assessed by Modified\n                    <scp>MD<\/scp>\n                    Anderson Criteria: An Open\u2010Label Phase 2 Study"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1991-4166","authenticated-orcid":false,"given":"Fumiya","family":"Hongo","sequence":"first","affiliation":[{"name":"Department of Urology Kyoto Prefectural University of Medicine  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutomo","family":"Nakai","sequence":"additional","affiliation":[{"name":"Department of Urology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nozawa","sequence":"additional","affiliation":[{"name":"Department of Urology Kindai University Faculty of Medicine  Osaka Japan"},{"name":"Department of Urology National Hospital Organization Osaka Minami Medical Center  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taigo","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Urology Osaka University, Graduate School of Medicine  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadanori","family":"Kamikawa","sequence":"additional","affiliation":[{"name":"Department of Urology Osaka City General Hospital  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tamada","sequence":"additional","affiliation":[{"name":"Department of Urology Bell Land General Hospital  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology Japanese Red Cross Kyoto Daiichi Hospital  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Soeda","sequence":"additional","affiliation":[{"name":"Japan Medical Affairs, Japan Oncology Business Unit Takeda Pharmaceutical Company Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Tsubouchi","sequence":"additional","affiliation":[{"name":"Japan Medical Affairs, Japan Oncology Business Unit Takeda Pharmaceutical Company Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Osaka","sequence":"additional","affiliation":[{"name":"Japan Medical Affairs, Japan Oncology Business Unit Takeda Pharmaceutical Company Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Urology Kindai University Faculty of Medicine  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr362"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.07.003"},{"issue":"4","key":"e_1_2_12_4_1","first-page":"163","article-title":"Paraneoplastic Syndromes in Urologic Malignancy: The Many Faces of Renal Cell Carcinoma","volume":"4","author":"Palapattu G.","year":"2002","journal-title":"Reviews in Urology"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.2170"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105115"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-017-1704-4"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2020.100315"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1261"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds463"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9997"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0174"},{"key":"e_1_2_12_13_1","unstructured":"European Association of Urology \u201cRenal Cell Carcinoma Guidelines [Internet]. The Netherlands. 2020 \u201daccessed at May 27 2025 https:\/\/uroweb.org\/guidelines\/renal\u2010cell\u2010carcinoma\/summary\u2010of\u2010changes\/2020."},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7352"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.181"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.1.80"},{"key":"e_1_2_12_19_1","unstructured":"K.Yamada F.Hongo S.Tamada et\u00a0al. \u201cDevelopment of Modified MD Anderson Criteria and Initial Experience: Evaluation of Bone Metastasis Response to Cabozantinib Monotherapy in Renal Cell Carcinoma [Poster ROP30\u20104] \u201d Presented at the Japan Radiology Congress April 10\u201313 2025; Yokohama Japan."},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30107-3"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0164-0"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1932-2"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07903-8"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9111499"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35181"},{"key":"e_1_2_12_26_1","first-page":"2443","article-title":"Value of Procollagen Type 1 Amino\u2010Terminal Propeptide in Patients With Renal Cell Carcinoma","volume":"28","author":"Klepzig M.","year":"2008","journal-title":"Anticancer Research"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.2152\/jmi.55.106"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08630-w"},{"key":"e_1_2_12_29_1","article-title":"Targeting RANKL in Metastasis","volume":"3","author":"Dougall W. C.","year":"2014","journal-title":"Bone Reports"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15390"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70495","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iju.70495","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:23:41Z","timestamp":1781861021000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.70495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/iju.70495"],"URL":"https:\/\/doi.org\/10.1111\/iju.70495","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70495"}}